Novartis
NEWS
In a 56-page response to the investigation from the U.S. Food and Drug Administration, Novartis said the Kaspar brothers personally manipulated or instructed others to alter some of the preclinical data that ultimately led to the approval of the $2.1 million priced SMA therapy.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Novartis, a leader reimagining rheumatology and immunodermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with nr-axSpA (non-radiographic axial spondyloarthritis).
The trial is still ongoing, but met its primary endpoint of ASAS40.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Novartis Chief Executive Officer Vas Narasimhan has pledged the company will be more forthcoming with the U.S. Food and Drug Administration and other regulatory agencies regarding data mismanagement and manipulations in the future.
JOBS
IN THE PRESS